MedTrace Logo

Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema

NCT00737971 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2016-05-03

No results posted yet for this study

Summary

Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema

Conditions

Interventions

DRUG

Bevacizumab intravitreal

Bevacizumab intravitreal 0.05 ml/1.25 mg - administered on D0, Week 4, Week 8

DRUG

Triamcinolone

Intravitreal 0.1 ml/4 mg, D0, Week 4 and Week 8

DRUG

Triamcinolone + Bevacizumab

Intravitreal triamcinolone 0.1 ml/4 mg + bevacizumab 0.05 ml/1.25 mg simultaneously on D0, week 4, Week 8

Sponsors & Collaborators

  • Rubens Belfort Jr.

    lead OTHER

Principal Investigators

  • Rubens Belfort Jr, MD · Federal University of São Paulo / Dept. of OPhthalmology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2012-12-31
Completion
2013-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00737971 on ClinicalTrials.gov